abs14.txt	background		although	metastasis	is	ultimately	responsible	for	about	90%	of	breastcancer	mortality	the	vast	majority	breast-cancer-related	deaths	are	due	toprogressive	recurrences	from	non-metastatic	disease	current	adjuvant	therapiesare	unable	to	prevent	progressive	a	significant	fraction	ofpatients	with	breast	cancer	autologous	tumor	cell	vaccines	(atcvs)	safeand	potentially	useful	strategy	recurrence	in	apersonalized	and	patient-specific	manner	following	standard-of-care	tumorresection	given	high	intra-patient	inter-patient	heterogeneity	it	important	understand	which	factors	influence	immunogenicityof	cells	order	maximize	atcv	effectiveness	methods	relative	immunogenicity	two	murine	carcinomas	4t1	andemt6	were	compared	prophylactic	vaccination-tumor	challenge	model	differences	surface	expression	antigen-presentation-related	andcostimulatory	molecules	along	immunosuppressive	cytokineproduction	crispr/cas9	technology	was	used	modulate	tumor-derived	cytokinesecretion	impacts	cytokine	deletion	on	splenomegaly	myeloid-derivedsuppressor	(mdsc)	accumulation	assessed	results	mice	vaccinated	an	emt6	vaccine	exhibited	significantly	greaterprotective	immunity	than	hybrid	vaccinationstudies	revealed	that	vaccination	induced	both	local	systemic	immuneimpairments	there	between	inthe	costimulatory	major	disparities	secretion	ofimmunosuppressive	cytokines	likely	accounts	immunogenicitybetween	lines	ablation	one	particular	granulocyte-colony	stimulating	factor	(g-csf)	reversed	mdsc	andsplenomegaly	furthermore	g-csf	inhibition	enhanced	theimmunogenicity	4t1-based	extent	all	micedeveloped	complete	protective	conclusions	express	levels	have	thepotential	diminish	or	abrogate	efficacy	atcvs	fortunately	this	study	demonstrates	genetic	immunosuppressivecytokines	such	as	can	enhance	cancercell-based	strategies	combine	immunosuppressivefactors	immune	stimulatory	co-formulations	already	under	development	mayhelp	reach	their	full	potential
